Gimbal Financial Sells 835 Shares of Eli Lilly and Company $LLY

Gimbal Financial trimmed its stake in shares of Eli Lilly and Company (NYSE:LLY) by 4.6% during the second quarter, Holdings Channel reports. The firm owned 17,160 shares of the company’s stock after selling 835 shares during the period. Eli Lilly and Company comprises about 8.2% of Gimbal Financial’s holdings, making the stock its 7th largest position. Gimbal Financial’s holdings in Eli Lilly and Company were worth $13,377,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the business. WestEnd Advisors LLC boosted its stake in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth $27,000. Citizens National Bank Trust Department boosted its position in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after buying an additional 27 shares during the period. IMG Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company in the second quarter worth $35,000. Finally, Financial Gravity Asset Management Inc. acquired a new stake in shares of Eli Lilly and Company in the first quarter worth $40,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently issued reports on LLY shares. HSBC lifted their price objective on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. UBS Group dropped their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Morgan Stanley decreased their price objective on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a report on Friday, October 3rd. Finally, Daiwa Capital Markets downgraded Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective on the stock. in a report on Sunday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $938.61.

Eli Lilly and Company Price Performance

LLY opened at $799.85 on Wednesday. The stock has a market cap of $757.03 billion, a P/E ratio of 52.28, a P/E/G ratio of 1.16 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $935.63. The company has a fifty day simple moving average of $759.77 and a 200 day simple moving average of $766.43.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s revenue for the quarter was up 37.6% compared to the same quarter last year. During the same period in the prior year, the business earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Insiders Place Their Bets

In other news, Director Jamere Jackson bought 200 shares of the business’s stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director owned 9,402 shares of the company’s stock, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director J Erik Fyrwald bought 1,565 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. The trade was a 2.14% increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 4,514 shares of company stock worth $2,894,841 in the last three months. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.